{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:13:14Z","timestamp":1777111994048,"version":"3.51.4"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T00:00:00Z","timestamp":1448496000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:p>Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are infrequent autoimmune cholestatic liver diseases, that disproportionate to their incidence and prevalence, remain very important causes of morbidity and mortality for patients with liver disease. Mechanistic insights spanning genetic risks and biological pathways to liver injury and fibrosis have led to a renewed interest in developing therapies beyond ursodeoxycholic acid that are aimed at both slowing disease course and improving quality of life. International cohort studies have facilitated a much greater understanding of disease heterogeneity, and in so doing highlight the opportunity to provide patients with a more individualized assessment of their risk of progressive liver disease, based on clinical, laboratory, or imaging findings. This has led to a new approach to patient care that focuses on risk stratification (both high and low risk); and furthermore allows such stratification tools to help identify patient subgroups at greatest potential benefit from inclusion in clinical trials. In this article, we review the applicability and validity of risk stratification in autoimmune cholestatic liver disease, highlighting strengths and weaknesses of current and emergent approaches. (H<jats:sc>epatology<\/jats:sc> 2016;63:644\u2013659)<\/jats:p>","DOI":"10.1002\/hep.28128","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T07:27:03Z","timestamp":1440055623000},"page":"644-659","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":63,"title":["Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists"],"prefix":"10.1097","volume":"63","author":[{"given":"Palak J.","family":"Trivedi","sequence":"first","affiliation":[{"name":"National Institute for Health Research (NIHR), Birmingham Liver Biomedical Research Unit (BRU), and Center for Liver Research,University of Birmingham,Birmingham,United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[{"name":"National Reference Center for Inflammatory Diseases of the Biliary Tract (MIVB), Rare Liver Diseases Health Network (FILFOIE), Saint\u2010Antoine Hospital,Assistance Publique\u2010H\u00f4pitaux de Paris (APHP),Paris,France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Pares","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Cl\u00ednic, CIBERehd, IDIBAPS,University of Barcelona,Barcelona,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[{"name":"National Institute for Health Research (NIHR), Birmingham Liver Biomedical Research Unit (BRU), and Center for Liver Research,University of Birmingham,Birmingham,United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2015,11,26]]},"reference":[{"key":"hep28128-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"hep28128-bib-0002-20241017","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","year":"2015","journal-title":"Gut"},{"key":"hep28128-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/j.gastro.2008.07.019","article-title":"Portal hypertension and primary biliary cirrhosis: effect of long\u2010term ursodeoxycholic acid treatment","volume":"135","year":"2008","journal-title":"Gastroenterology"},{"key":"hep28128-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jhep.2013.04.010","article-title":"A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score","volume":"59","year":"2013","journal-title":"J Hepatol"},{"key":"hep28128-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2040622313478646","article-title":"Treatment of autoimmune liver disease: current and future therapeutic options","volume":"4","year":"2013","journal-title":"Ther Adv Chronic Dis"},{"key":"hep28128-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"hep28128-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","year":"2009","journal-title":"Hepatology"},{"key":"hep28128-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow\u2010up study","volume":"147","year":"2014","journal-title":"Gastroenterology"},{"key":"hep28128-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","year":"2013","journal-title":"Gastroenterology"},{"key":"hep28128-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long\u2010term prognosis in primary biliary cirrhosis","volume":"48","year":"2008","journal-title":"Hepatology"},{"key":"hep28128-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long\u2010term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","year":"2006","journal-title":"Gastroenterology"},{"key":"hep28128-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2010.05.026","article-title":"The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow\u2010up","volume":"53","year":"2010","journal-title":"J. Hepatol."},{"key":"hep28128-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population\u2010based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep28128-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2036.2012.05223.x","article-title":"Review article: overlap syndromes and autoimmune liver disease","volume":"36","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"hep28128-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: The UK\u2010PBC national study","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep28128-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow\u2010up for up to 28 years","volume":"123","year":"2002","journal-title":"Gastroenterology"},{"key":"hep28128-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/liv.12560","article-title":"Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis","volume":"35","year":"2015","journal-title":"Liver Int"},{"key":"hep28128-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study","volume":"102","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"hep28128-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.38.4.610","article-title":"Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis","volume":"38","year":"1996","journal-title":"Gut"},{"key":"hep28128-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","article-title":"High lifetime risk of cancer in primary sclerosing cholangitis","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"hep28128-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/003655202760373434","article-title":"Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation","volume":"37","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"hep28128-bib-0022-20241017","first-page":"126","article-title":"Primary biliary cirrhosis: prediction of short\u2010term survival based on repeated patient visits","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"hep28128-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic acid\u2010treated patients with primary biliary cirrhosis. Results of a 10\u2010yr cohort study involving 297 patients","volume":"101","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"hep28128-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long\u2010term outcome","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"hep28128-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long\u2010term histological progression in primary biliary cirrhosis","volume":"105","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"hep28128-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/apt.12522","article-title":"Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29\u2010year cohort study","volume":"38","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"hep28128-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long\u2010term prognosis of primary biliary cirrhosis: results of a 14\u2010year cohort study","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep28128-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"hep28128-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s00535-009-0090-2","article-title":"Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population","volume":"44","year":"2009","journal-title":"J Gastroenterol"},{"key":"hep28128-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol\u2010treated patients","volume":"122","year":"2002","journal-title":"Gastroenterology"},{"key":"hep28128-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"S805","DOI":"10.1016\/S0168-8278(15)31394-5","article-title":"Histological stage is relevant for risk\u2010stratification in primary biliary cirrhosis","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep28128-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1016\/S0168-8278(15)31380-5","article-title":"Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation\u2010free survival in patients with primary biliary cirrhosis","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep28128-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.jhep.2014.07.036","article-title":"AST\/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"hep28128-bib-0034-20241017","article-title":"The UK\u2010PBC risk scores: derivation and validation of a scoring system for long\u2010term prediction of end\u2010stage liver disease in primary biliary cirrhosis","year":"2015","journal-title":"Hepatology"},{"key":"hep28128-bib-0035-20241017","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","year":"2015","journal-title":"Gastroenterology"},{"key":"hep28128-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"hep28128-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High\u2010dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","year":"2009","journal-title":"Hepatology"},{"key":"hep28128-bib-0038-20241017","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","year":"2011","journal-title":"Dig Liver Dis"},{"key":"hep28128-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/apt.12979","article-title":"Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis","volume":"40","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"hep28128-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","year":"2013","journal-title":"J Hepatol"},{"key":"hep28128-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/S0168-8278(15)30093-3","article-title":"Early clinical features associated with long\u2010term risk of transplantation in primary sclerosing cholangitis: results from the UK\u2010PSC Consortium","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep28128-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association Between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep28128-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jhbp.238","article-title":"Short\u2010term prognostic factors for primary sclerosing cholangitis: prognostic factors for PSC","volume":"22","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"hep28128-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti\u2010gp210 and anti\u2010centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep28128-bib-0045-20241017","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","article-title":"Extrahepatic autoimmune conditions associated with primary biliary cirrhosis","volume":"48","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"hep28128-bib-0046-20241017","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ajg.2011.375","article-title":"The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice","volume":"107","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"hep28128-bib-0047-20241017","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/hep.26977","article-title":"Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4\u2010associated cholangitis from primary sclerosing cholangitis","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"hep28128-bib-0048-20241017","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/j.1572-0241.2006.00772.x","article-title":"Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis","volume":"101","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"hep28128-bib-0049-20241017","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.dld.2014.06.010","article-title":"The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis","volume":"46","year":"2014","journal-title":"Dig Liver Dis"},{"key":"hep28128-bib-0050-20241017","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2010.02.030","article-title":"In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival","volume":"53","year":"2010","journal-title":"J Hepatol"},{"key":"hep28128-bib-0051-20241017","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1572-0241.2004.04067.x","article-title":"Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis","volume":"99","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"hep28128-bib-0052-20241017","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cgh.2011.08.027","article-title":"Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis","volume":"9","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep28128-bib-0053-20241017","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2012.02.034","article-title":"IBD is associated with an increase in carcinoma in PSC irrespective of the presence of dominant bile duct stenosis","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"hep28128-bib-0054-20241017","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1055\/s-0030-1255527","article-title":"Validation of a cholangiographic prognostic model in primary sclerosing cholangitis","volume":"42","year":"2010","journal-title":"Endoscopy"},{"key":"hep28128-bib-0055-20241017","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.26620","article-title":"Radiologic course of primary sclerosing cholangitis: assessment by three\u2010dimensional magnetic resonance cholangiography and predictive features of progression","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"hep28128-bib-0056-20241017","doi-asserted-by":"crossref","first-page":"S794","DOI":"10.1016\/S0168-8278(15)31371-4","article-title":"Ability of a simple radiologic score, assessed by three dimensional magnetic resonance cholangiography (MRC), to predict clinical outcome of patients with primary sclerosing cholangitis (PSC)","volume":"62","year":"2015","journal-title":"J Hepatol"},{"key":"hep28128-bib-0057-20241017","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bpg.2011.10.003","article-title":"Medical and endoscopic therapy of primary sclerosing cholangitis","volume":"25","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"hep28128-bib-0058-20241017","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/MEG.0b013e3283554bbf","article-title":"Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis; a 25 year single centre experience","volume":"24","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep28128-bib-0059-20241017","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1572-0241.2004.04106.x","article-title":"Dominant strictures in patients with primary sclerosing cholangitis","volume":"99","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"hep28128-bib-0060-20241017","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jhep.2009.01.023","article-title":"Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"hep28128-bib-0061-20241017","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.gie.2009.10.041","article-title":"Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long\u2010term treatment","volume":"71","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"hep28128-bib-0062-20241017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.51.5.731","article-title":"Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis","volume":"51","year":"2002","journal-title":"Gut"},{"key":"hep28128-bib-0063-20241017","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/jhep.2002.33202","article-title":"Small\u2010duct primary sclerosing cholangitis: a long\u2010term follow\u2010up study","volume":"35","year":"2002","journal-title":"Hepatology"},{"key":"hep28128-bib-0064-20241017","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small\u2010duct primary sclerosing cholangitis","volume":"134","year":"2008","journal-title":"Gastroenterology"},{"key":"hep28128-bib-0065-20241017","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.humpath.2012.09.017","article-title":"Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems","volume":"44","year":"2013","journal-title":"Hum Pathol"},{"key":"hep28128-bib-0066-20241017","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/liv.12620","article-title":"Primary biliary cirrhosis: proposal for a new simple histological scoring system","volume":"35","year":"2015","journal-title":"Liver Int"},{"key":"hep28128-bib-0067-20241017","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/gut.49.2.276","article-title":"Jaundice in non\u2010cirrhotic primary biliary cirrhosis: the premature ductopenic variant","volume":"49","year":"2001","journal-title":"Gut"},{"key":"hep28128-bib-0068-20241017","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","article-title":"Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis","volume":"12","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep28128-bib-0069-20241017","article-title":"Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis","year":"2015","journal-title":"J Hepatol"},{"key":"hep28128-bib-0070-20241017","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography\u2010based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","year":"2012","journal-title":"Hepatology"},{"key":"hep28128-bib-0071-20241017","first-page":"887","article-title":"Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis","volume":"43","year":"2011","journal-title":"Dig Liver Dis"},{"key":"hep28128-bib-0072-20241017","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"hep28128-bib-0073-20241017","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/hep.22517","article-title":"Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis (ELF) assay","volume":"48","year":"2008","journal-title":"Hepatology"},{"key":"hep28128-bib-0074-20241017","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant\u2010free survival in primary sclerosing cholangitis","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep28128-bib-0075-20241017","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.crohns.2011.07.015","article-title":"A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease","volume":"6","year":"2012","journal-title":"J Crohns Colitis"},{"key":"hep28128-bib-0076-20241017","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","year":"2009","journal-title":"Gastroenterology"},{"key":"hep28128-bib-0077-20241017","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/s-0034-1383733","article-title":"Old and novel therapies for primary biliary cirrhosis","volume":"34","year":"2014","journal-title":"Semin Liver Dis"},{"key":"hep28128-bib-0078-20241017","doi-asserted-by":"crossref","first-page":"h870","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","year":"2015","journal-title":"BMJ"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28128","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201602000-00035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T23:35:08Z","timestamp":1729208108000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201602000-00035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,26]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.28128","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,26]]},"assertion":[{"value":"2015-07-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}